📊 TXG Key Takeaways
Is 10x Genomics, Inc. (TXG) a Good Investment?
10x Genomics maintains exceptional financial strength with $490M cash, zero debt, and positive free cash flow of $24.5M despite net losses, indicating underlying business viability. However, the company's -11.3% operating margin and unprofitability at scale, combined with modest 5.2% revenue growth, require a clear demonstration of margin expansion before an upgrade is warranted.
10x Genomics, Inc. Key Strengths (TXG)
- Exceptional balance sheet with $490M cash and zero long-term debt provides significant financial flexibility
- Strong gross margins of 70.4% demonstrate product quality and pricing power in laboratory analytics markets
- Positive operating cash flow of $26.1M and free cash flow of $24.5M (16.3% FCF margin) indicate sustainable business fundamentals despite net losses
- Excellent liquidity with 5.90x current ratio and minimal capex requirements of $1.6M provide runway for operations
TXG Stock Risks: 10x Genomics, Inc. Investment Risks
- Operating loss of $17.0M and negative net margin of -8.9% at revenue scale of $151M suggests structural profitability challenges or inefficient cost structure
- Negative return metrics (ROE -1.7%, ROA -1.3%) indicate current value destruction despite strong balance sheet
- Modest revenue growth of 5.2% YoY insufficient to demonstrate scale potential in laboratory instruments sector
- Significant gap between positive FCF and negative net income suggests material non-cash charges or accounting items masking operational challenges
- Unprofitability trend unsustainable long-term even with $490M cash buffer without clear cost management plan
Key Metrics to Watch
- Operating margin progression and path to breakeven within 12-24 months
- Revenue growth acceleration above 5% to demonstrate market demand
- Operating cash flow sustainability and working capital efficiency
- Gross margin stability and operating expense ratio trends
10x Genomics, Inc. (TXG) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.90x current ratio provides a solid financial cushion.
TXG Profit Margin, ROE & Profitability Analysis
TXG vs Industrial Sector: How 10x Genomics, Inc. Compares
How 10x Genomics, Inc. compares to Industrial sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is 10x Genomics, Inc. Stock Overvalued? TXG Valuation Analysis 2026
Based on fundamental analysis, 10x Genomics, Inc. has mixed fundamental signals relative to the Industrial sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
10x Genomics, Inc. Balance Sheet: TXG Debt, Cash & Liquidity
TXG Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: 10x Genomics, Inc.'s revenue has grown significantly by 31% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.18 indicates the company is currently unprofitable.
TXG Revenue Growth, EPS Growth & YoY Performance
TXG Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $150.8M | -$13.5M | $-0.10 |
| Q3 2025 | $149.0M | -$27.3M | $-0.22 |
| Q2 2025 | $153.1M | $180.0K | $0.00 |
| Q1 2025 | $141.0M | -$34.4M | $-0.28 |
| Q3 2024 | $151.7M | -$35.8M | $-0.30 |
| Q2 2024 | $146.8M | -$37.9M | $-0.32 |
| Q1 2024 | $134.3M | -$50.7M | $-0.44 |
| Q3 2023 | $131.1M | -$41.9M | $-0.37 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
10x Genomics, Inc. Dividends, Buybacks & Capital Allocation
TXG SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for 10x Genomics, Inc. (CIK: 0001770787)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TXG
What is the AI rating for TXG?
10x Genomics, Inc. (TXG) has an AI grade of B with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TXG's key strengths?
Claude: Exceptional balance sheet with $490M cash and zero long-term debt provides significant financial flexibility. Strong gross margins of 70.4% demonstrate product quality and pricing power in laboratory analytics markets.
What are the risks of investing in TXG?
Claude: Operating loss of $17.0M and negative net margin of -8.9% at revenue scale of $151M suggests structural profitability challenges or inefficient cost structure. Negative return metrics (ROE -1.7%, ROA -1.3%) indicate current value destruction despite strong balance sheet.
What is TXG's revenue and growth?
10x Genomics, Inc. reported revenue of $150.8M.
Does TXG pay dividends?
10x Genomics, Inc. does not currently pay dividends.
Where can I find TXG SEC filings?
Official SEC filings for 10x Genomics, Inc. (CIK: 0001770787) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TXG's EPS?
10x Genomics, Inc. has a diluted EPS of $-0.10.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is TXG's fundamental grade?
Based on our AI fundamental analysis in June 2026, 10x Genomics, Inc. has a B grade with 72% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is TXG stock overvalued or undervalued?
Valuation metrics for TXG: ROE of -1.7% (sector avg: 15%), net margin of -8.9% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
What is TXG's AI grade for 2026?
Our dual AI analysis gives 10x Genomics, Inc. a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TXG's free cash flow?
10x Genomics, Inc.'s operating cash flow is $26.1M, with capital expenditures of $1.6M. FCF margin is 16.3%.
How does TXG compare to other Industrial stocks?
Vs Industrial sector averages: Net margin -8.9% (avg: 10%), ROE -1.7% (avg: 15%), current ratio 5.90 (avg: 1.8).